Latest Publications

Share:

BIOSECURE Act Enacted

On December 18, 2025, President Trump signed into law the National Defense Authorization Act (The “NDAA”). Among its provisions, the NDAA includes an updated version of the BIOSECURE Act (the “Act”)....more

Causam v. ITC: A New Development and Potential Cautionary Tale in Patent Assignments

In the recent case Causam Enterprises, Inc. v. International Trade Commission, the United States Court of Appeals for the Federal Circuit (the “CAFC”) found that an invention assignment agreement that broadly assigned the...more

Senate Passes 2026 NDAA Including BIOSECURE Act Amendment

On Thursday, October 9, 2025, the Senate passed its version of the 2026 National Defense Authorization Act (the “NDAA”), which includes the latest version of the BIOSECURE Act (the “Amendment”) as an amendment. The House...more

Reintroduction of the BIOSECURE Act: Potential Impact on the Biotechnology Industry

The BIOSECURE Act (“the Act”), which received bipartisan support in both the U.S. House of Representatives and U.S. Senate in 2024 but was not ultimately passed into law, has re-emerged in this session of Congress, but with...more

“Winning the Race: America’s AI Action Plan” – Key Pillars, Policy Actions, and Future Implications

On July 23, 2025, the White House unveiled its “Winning the Race: America’s AI Action Plan” (the “Plan”), a comprehensive roadmap outlining a series of policy goals and recommended policy actions intended “for near-term...more

A Tale of Three Cases: How Fair Use Is Playing Out in AI Copyright Lawsuits

In two recent Northern District of California decisions, AI companies prevailed on a fair use defense after being accused of infringing copyrights in works used to train AI models. The decisions, on their face, seem to...more

Protecting Trade Secrets in FDA Submissions from FOIA Disclosure in the Wake of FDA Layoffs

In the wake of recent mass layoffs at the U.S. Food and Drug Administration (“FDA”), the FDA is likely to have fewer resources to manage its regulatory responsibilities. One area that may be significantly impacted by such...more

The Illumina Ban and What It Means for Life Science Companies

Amid increasing economic tensions with the United States, China recently announced that it would ban Illumina, a U.S.-based company and the world’s leading producer of gene-sequencing machines, from importing its gene...more

Does Training an AI Model Using Copyrighted Works Infringe the Owners’ Copyright? An Early Decision Says, “Yes.”

As has been widely reported, including in our year-end summary of the current state of artificial intelligence (“AI”)-related copyright litigation, AI providers are currently facing a wave of lawsuits1 from copyright owners...more

Life Sciences Under the Microscope: Key 2024 Takeaways and What’s Ahead for 2025

The life sciences industry experienced a dynamic year in 2024. As the public markets gained traction, IPO activity and venture investment saw a resurgence, signaling renewed investor confidence and reflecting sustained...more

Expected Changes to IP Policy under the Second Trump Administration

Intellectual property (“IP”) policy does not weigh heavily on most voters’ minds, and so is not often addressed in presidential campaigns. This past campaign was no different – President-elect Donald Trump did not expressly...more

An End-of-Year Update to the Current State of AI Related Copyright Litigation

In April 2024, we published a summary of the then current state of artificial intelligence (“AI”)-related copyright litigation. Since that publication, new theories for complaints and defenses have emerged in this space. As...more

Controlled Digital Lending after Hachette Book Group, Inc. v. Internet Archive

The future of controlled digital lending (“CDL”), the digital equivalent of traditional library lending, is uncertain after the United States Court of Appeals for the Second Circuit’s judgment in Hachette Book Group, Inc. v....more

14 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide